The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
Invitrocue Limited (ASX: IVQ) is an innovative life sciences company that specialises in developing ground-breaking 3D cell-based models derived from liver and tumour tissues. Headquartered in Singapore and with operations in Australia, Germany, Hong Kong and China. Invitrocue’s Onco-PDO test enables a personalised and patient-specific approach to recreating cancer cells (organoids) that can be cultured in laboratories for testing against a panel of cancer drugs to support clinical, economical and lifestyle decision making.
Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). Invitrouce’s products have been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.
Using advanced organoid technology, Invitrocue has developed a personalised test, Onco-PDO (Patient-Derived-Organoids), that allows physicians to more effectively personalise cancer treatment for their patients. The Onco-PDO test is a chemosensitivity and chemoresistance test that offers a more targeted and personalised approach to cancer treatment by creating a clinically-relevant predictive in vitro model that quantifies tumour response to stand-of-care chemotherapeutics. The information provided by this test assists physician in developing a more informed and individually tailored treatment for cancer patient.
Invitrocue’s Laboratory Facilities established in Europe and Asia, are an important milestone in the international expansion of Invitrocue’s capability to help caner patients receive the “Right Drug at the Right Time”.
Proprietary HiMice (Humanised Mice) are a humanised mouse model with a stably reconstituted human immune system. Our animal models have enabled research in areas such as oncology, liver disease, auto-immune and infectious diseases.